Autologous platelet lysate local injections for the treatment of refractory lateral epicondylitis by Xun-xiang Tan et al.
RESEARCH ARTICLE Open Access
Autologous platelet lysate local injections
for the treatment of refractory lateral
epicondylitis
Xun-xiang Tan1, Hai-yang Ju1, Wei Yan1, Hong-jiang Jiang1*, Jin-ping Su1, Hua-jun Dong1, Ling-shuang Wang2
and De-bao Zou1
Abstract
Background: The purpose of this study was to investigate the efficacy and safety of autologous platelet lysate
(APL) local injections in reducing pain and improving function in patients with refractory lateral epicondylitis.
Methods: A total of 56 patients with refractory lateral epicondylitis were enrolled in this study. All the patients
received three injections in one course of treatment. Subjective assessments include visual analog scale (VAS) pain
score and Mayo elbow score before injection (baseline) and at 1, 6, and 12 months after injection.
Results: Significant differences were observed in VAS and Mayo scores at baseline and at 1, 6, and 12 months after
injection. Overall, the injections of APL improved local symptoms and all the patients recovered to normal elbow
function with 12 months follow-up.
Conclusions: Local injections of APL resulted in favorable clinical outcomes for the treatment of lateral
epicondylitis. APL could be clinically effective in the treatment of lateral epicondylitis.
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Background
Lateral epicondylitis (LE), commonly called tennis
elbow, is one of the most common enthesopathies in
sports medicine. The primary symptoms included per-
sistent pain and tenderness over the lateral epicondyle
with the inability in carrying out activities of daily living
(ADL). LE affects about 1–3 % of the general population
and peaks in the fourth and fifth decades of life [1–3].
A wide variety of therapies have been trialed in the
treatment of LE. Initially, treatments for LE include rest,
stretching, bracing, formal physical therapy, small
needle-knife therapy, anti-inflammatory medication, and
activity modification. Cortisone is the next option in pa-
tients who do not respond to these treatments. Although
the majority of patients improve with conservative
management, surgery is needed in 10 % of cases in
whom these treatments are ineffective. Besides, these
treatments only can improve the symptom; but for the
intractable and refractory LE, the best management
strategies remain controversial [4].
Most specialists think that the pathology of LE is de-
generative, the noninflammatory, chronically degenera-
tive changes in the extensor carpi radialis brevis muscle
origins being identified during surgery [5]. The nature of
the disease is common extensor tendon injuries aggra-
vated by active and resisted wrist extension and/or re-
petitive rotation and extension and flexion of the
forearm [6].
With the development of molecular biology and regen-
erative medicine, the use of endogenous growth factors
has shown promising results in vitro and in vivo in LE
treatment. Numerous studies have examined the effects
of growth factors; demonstrating benefits include
improved cellular remodeling and decreased healing
time [7].
Plasma rich in growth factors has been proved to be
safe and effective in treating tendinopathy such as
Achilles tendinopathy, patellar tendinopathy, and rotator
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cuff tears in sports medicine. They have been shown to
induce the migration of reparative cells to an injection
site, reverse the pathological changes of the enthesiopa-
thy, restore normal structure, relieve symptoms, and re-
duce the recurrence [8–10].
Autologous platelet lysates (APL) contain a myriad of
bioactive growth factors such as vascular endothelial
growth factor, insulin-like growth factor, and transform-
ing growth factor; these histo-promotive substances
could influence tissue repairing through angiogenesis,
cellular chemotaxis, removal of tissue debris, and recon-
struction of extracellular matrix [11, 12].
Thus, we discussed the potential roles and advantages of
APL and conducted the retrospective study to evaluate
the short-term efficacy of local APL injections in reducing
pain and improving function in patients with LE. Great
clinical improvement with APL therapy is expected.
Methods
Patients
This study was approved by the ethics committee of
Wendeng Orthopaedic Hospital of Shandong Province.
Written informed consents were obtained from all
participants.
Between June 2012 and May 2014, 56 patients (21 men
and 35 women) who met the eligibility criteria were in-
vited to enter the trial. The average age at the primary
presentation of symptoms was 45 years (range, 36–62).
The average time from the primary presentation of symp-
toms to the treatment was 9.7 months (range, 6–18). All
the patients were followed up through outpatients after
the treatment.
Eligibility criteria
Patients with severe lateral elbow pain resisting wrist
and forearm extension and patients who had persistent
pain and tenderness over the lateral epicondyle and af-
fected ADL were involved. Diagnosis of LE was con-
firmed on an ultrasound. Patients were required to have
symptoms for at least 3 months following initial presen-
tation and to have failed conservative treatments.
Sixteen patients only received the treatment of massage,
acupuncture, physiotherapy, and nonsteroidal anti-
inflammatory medication. Thirteen patients only
received the treatment of steroid, including steroid un-
guent and steroid injection. Seventeen patients received
all the conservative treatments above. All patients had
no significant improvement of symptoms 6 to 14 weeks
after the treatments.
Patients were excluded if they met any of the following
conditions: patients with cervical spondylosis, any trauma
or prior surgical intervention to the elbow, history of in-
flammatory arthropathy or a tendon tear, rheumatic joint
disease, joint limitations due to a previous radial and ulna
bone fracture, local osteoporosis, and neurological deficits
in the ipsilateral upper limb.
Preparation of autologous platelet lysates
Approximately 60 ml of peripheral vein blood was with-
drawn from each patient into a syringe containing 6 ml
of a citrate anticoagulant. After transferring into several
centrifuge tubes, the peripheral blood were centrifuged
at 1048 r min−1 for 25 min at room temperature
(Thermo, USA) and then three layers were separated.
Platelet-rich plasma (PRP) in the middle layer (about
20 ml) was withdrawn and subpackaged into three vac-
uum tubes (Fisher, USA). This plasma contains concen-
trated platelets about three times baseline in an
nonactivated form. Then, the tubes were cryopreserved
at −80 °C overnight, and then, one of them was resusci-
tated in a 37 °C water bath kettle for 5 min. After repeat-
edly freeze-thawed more than twice, the plasma contains
a variety of growth factors including platelet-derived
growth factor, transforming growth factor-beta, and vas-
cular endothelial growth factor.
The thawed and activated plasma was centrifuged at
3054 r min−1 for 6 min (centrifugation radius is 9 cm) to
separate the platelet fragmentation in the under layer.
Deoxycycline (APP Pharm, USA) of 10 ug ml−1 was
added into the supernatant with a volume ratio of
1000:1, and then, the APL which contains the cocktail of
factors released by the platelets was obtained after filtra-
tion. The mean volume of APL injected in our series
was 3 ml for each infiltration.
Injection technique
1. The patient was asked in the sitting position.
Confirm the area to be treated by a tiny q-tip, mark
the maximum tenderness point, and sterilize with an
iodine solution.
2. A 25-G needle was inserted perpendicularly into the
periosteum. After withdrawing about 0.5 cm, 3 ml of
the buffered APL was injected into the area of
abnormality. A single skin portal with multiple
penetrations into the tendon by sloping the needle
to 60° is recommended so that the liquid disperse
fully into the humerus muscular fasciae. The
preferred method is to do this procedure under
ultra-sonic guidance [13].
3. Tampon the treated area for 3–5 min after injection
without moving the involved elbow. The injection
was carried out once a week with three injections in
one course of treatment.
Post-injection protocol
Vigorous activities such as strong gripping or lifting
should be avoided 1 week post-procedure. The use of
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nonsteroidal anti-inflammatory medication was prohib-
ited for the first 4 weeks after injection. Icing and eleva-
tion are recommended if necessary. After 2 weeks,
gradual strengthening and return to activity were
initiated.
Evaluation methods
Patients were evaluated using a visual analog scale (VAS)
to assess pain and Mayo score to assess elbow function
and patient satisfaction. The VAS score is a measure-
ment instrument to quantify the amount of pain re-
ported by the patient and scores range from 0 (no pain)
to 100 (severest pain) with five categories of pain (no
pain 0, mild pain 1–30, moderate pain 40–60, severe
pain 70–90, and the intolerable pain 100). The Mayo
score could reflect elbow function of the patient with
full mark of 100 include pain, movement, stability, and
ADL (Table 1). The VAS and Mayo scores were recorded
prior to the first procedure and at 1, 6, and 12 months
follow-up. Complications and patient satisfaction were
also recorded.
Longitudinal ultrasonography was performed on all
patients before injection and at 1 month after APL treat-
ment. Patients were examined in a sitting position with
the elbow flexed to 90°, the wrist pronated, and the arm
resting on a table [14]. We used a high-quality ultra-
sound scanner (EUB 900, Hitachi Medical Europe, Zug,
Switzerland) with a 14-MHz linear transducer. The
transducer was aligned with the long axis of the radius
over the common tendon origin. The common tendon
origin was examined with color Doppler US in the longi-
tudinal plane by moving the transducer from side to
side, locating the part with the most Doppler activity.
The color Doppler activity is usually seen in an area lim-
ited proximally by the tip of the lateral epicondyle and
distally by the humeroradial joint space. The superficial
border was the most superficial fibers, and the deep
border was the bone [14]. The size of the color Doppler
activity area is on behalf of the blood signal strength,
and the richer the blood signal, the heavier the degree of
inflammation.
Results
Fifty-six patients met our inclusion criteria. All the pa-
tients were followed up through outpatients after the
treatment. The overall average length of follow-up was
12 months (range, 9–16).
VAS pain scores
The average VAS pain scores at baseline were 72.8 ± 3.9
for all patients (Table 2), while mean VAS pain scores at
1 month follow-up were 19.8 ± 5.6 and the scores had
decreased to 8.2 ± 2.8 at 12 months follow-up (Fig. 1).
Particularly, at 1 month follow-up, the average VAS
score decreased by nearly 40 points from baseline and
there was a significant difference before and after APL
treatment (P < 0.01). The results showed that the appli-
cation of APL could reduce pain significantly.
Mayo elbow scores
Significant differences were observed relative to Mayo
score (P = 0.05) before and 1 month after APL injection.
Specifically, at 1 month after APL treatment, the mean
Mayo score had increased from 61.9 ± 3.0 to 89.6 ± 4.3
(Fig. 2). Mayo elbow scores had improved 44 % after
APL treatment. Furthermore, the mean Mayo scores
were 92.5 ± 3.3 at 6 months and 97.6 ± 2.1 at 12 months
(Table 2), reflecting good elbow function improvement
and efficacy after being treated with APL.
US evaluation
We presented three cases, and representative ultrasono-
gram graphs are shown in Fig. 2. The color Doppler ac-
tivities were very evident before injection (Fig. 3a–c).
However, the areas of color Doppler activity were much
smaller at 1 month after APL treatment in three patients
(Fig. 3d–f ). The results meant APL alleviated the inflam-
mation of LE.
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Complications
No adverse events were reported during the trial or at
the final follow-up of 12 months. There were no infec-
tions, and no patient required any further surgery. At
the final follow-up, all the patients had superior elbow
function and got good satisfaction.
Discussion
A tennis elbow patient who received conservative treat-
ment without relief of symptoms for 6 months is diffi-
cult to handle, and surgical management such as
minimally invasive surgery or arthroscopy surgery is
usually needed.
LE is typically attributed to activities that require the
repetitive use of soft tissues. Overuse of extensor tendon
leads to lower tendon repairing ability, and pathological
changes were observed. Histopathology studies in LE re-
veal degeneration and dysfunction; histological analysis
reveals increased vascularity, thinner and disordered col-
lagen fibers, and large interfibrillar mucoid patches and
vacuoles. Microscopic evaluation of the tendons does
not show any signs of inflammation [15].
Numerous clinical trials have been advocated for treat-
ing LE. Rompe extracted data from 10 clinical trials and
demonstrated the effectiveness of shock wave therapy
(SWT) for lateral elbow tendinopathy under well-
defined, restrictive conditions only [16]. Their analysis
suggested that there was no consensus for differentiating
between low-energy and high-energy shock waves as
multiple physical variables are involved. Their research
has further identified components that may possibly
have an adverse effect on the clinical outcome: enrol-
ment of acute, previously untreated patients; repetitive
application of low-energy SWT at monthly intervals; the
use of local anesthesia; and follow-up less than
3 months.
Several studies investigated the fundamental role of
the platelets in releasing factors able to support and ac-
celerate the healing process. Edwards [17] thinks the
underlying pathology of LE is not an inflammatory
tendinitis but a degenerative tendinosis; thus, anti-
inflammatory drugs should be replaced by a more bio-
logical approach for tissue renovation. Autologous blood
injections were carried out by them, and 79 % of the pa-
tients had significant pain relief after treatment. Mishra
and Pavelko [18] performed a cohort study comparing
local injection of buffered PRP with bupivacaine in 140
patients with chronic elbow tendinosis. The results
showed that 8 weeks after treatment, PRP group noted
60 % improvement versus 16 % improvement in the con-
trol group in their VAS scores. At the final follow-up,
PRP group reported 93 % reduction in pain compared
with before the treatment.
As a form of autologous cytokine therapy, PRP has
been investigated to induce the migration of reparative
cells to the injured tendon and enhance tendon vascular-
ity and improve the biomechanical properties, but not
all types of PRP have the same bioactivity. Traditional
PRP contains an increased concentration of white blood
cells (WBCs); Anitua thinks that these leukocytes could
cause pro-inflammatory effects due to the presence of
proteases and acid hydrolyses [19]. Besides, as a type of
Table 2 Mean VAS and Mayo scores at baseline and 1, 6, and 12 months after treatment with APL
Pre-treatment 1 month follow-up 6 months follow-up 12 months follow-up P value
Mean VAS score 72.8 ± 3.9 19.8 ± 5.6 11.3 ± 2.2 8.2 ± 2.8 <0.01
Mean Mayo score 61.9 ± 3.0 89.6 ± 4.3 92.5 ± 3.3 97.6 ± 2.1 <0.05
Data are presented as mean ± SD
Fig. 1 Mean VAS scores of patients at baseline and at 1, 6, and
12 months after injection. *P < 0.05 compared with the baseline
Fig. 2 Mean Mayo scores of patients at baseline and at 1, 6, and
12 months after injection. *P < 0.05 compared with the baseline
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WBC, neutrophil infiltration has been found to be re-
sponsible for the chronic inflammation seen in nonheal-
ing wound; healing of the wound will not occur until the
infiltration of neutrophils is reduced. Thus, the use of
PRP containing high levels of leukocytes may be ques-
tioned [20].
A number of studies have shown the different roles
of activated agent in PRP and the healing process
chain. Activation of PRP is being discussed in medical
literature. After activation, platelets release a burst of
proteins from their alpha granules, dense granules,
and lysosomes [21]. They contribute the numerous
biologically active molecules and provide platelets
with their healing properties. Within an hour of acti-
vation, 95 % of the granule’s previously manufactured
growth factors will be secreted [22].
In this study, we used a freeze-thawing method to acti-
vate platelets; after a high-speed centrifugation and
supernatant abstraction, APL without leukocytes was ob-
tained. The APL contains pools of bioactive substances
and signaling molecules which act as important roles in
cell behavior and tissue repair. Crespo et al. [23] con-
firmed that the addition of platelet lysate to a culture
medium could stimulate the proliferation of human
mesenchymal stem cell proliferation and chromosomal
stability.
The injection of APL into the degenerated humerus
is a simple and minimally invasive technique, which
helps to promote the restitution of ECM and regener-
ation of impaired tissue. In this study, we observed
highly significant differences relative to VAS and
Mayo scores before and 1, 6, and 12 months after
local APL injections. Importantly, at the 1 month
follow-up, normal elbow functions of all the patients
were achieved, reflecting good efficacy. Furthermore,
at 12 months post-injection, the patients have slighter
pain and recovered to normal bow function.
Our study is associated with several limitations such
as retrospective design and the lack of a control group.
Sustained efficacy should be further investigated in lon-
gitudinal and randomized controlled studies.
Conclusions
APL local injection therapy is used to initiate response
with LE patients who did not respond to conservative
treatment for 3 months. Our study findings suggest great
clinical improvement for the treatment of LE by APL
local injections, and there is no apparent increased risk
of complications associated with this procedure. A new,
nonsurgical option for the treatment of LE with excel-
lent safety and efficacy was provided through this study;
this therapy has the potential to serve as an alternative
to surgical intervention, and thus, health care costs were
reduced. Limitations of this preliminary study include
lack of a control group, lack of objective assessments,
small sample size, and the short-term results, and fur-
ther study is needed. A larger, multicenter, randomized
controlled trial is required to further assess the role of
APL in refractory LE treatment.
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Fig. 3 Ultrasonogram graphs of three representative cases before APL injection (a–c) and 1 month after APL treatment (d–f). The areas of color
Doppler activity were much smaller at 1 month after APL treatment than those before injection in three patients
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